Kye Pharmaceuticals partners with Hyloris Pharmaceuticals for the Development and Commercialization of Atomoxetine Oral Solution in Canada
Kye Pharmaceuticals Inc. ("Kye"), a Canadian specialty pharmaceutical company, announced its partnership with Hyloris Pharmaceuticals SA ("Hyloris"), a Belgium-based developer, manufacturer and global supplier of a novel, prescription, oral solution form of atomoxetine. Through this partnership, Kye becomes the exclusive Canadian rights holder for the Atomoxetine Oral Solution developed by Hyloris. Under the terms of the agreement, Kye is responsible for the registration and ...
Stijn Van Rompay John Mckendry Hyloris Pharmaceuticals Skye Pharmaceuticals Pharmaceuticals Inc Atomoxetine Oral Solution
Source: yahoo.com